Drug intelligence / Profile preview

chlorpheniramine + paracetamol + phenylephrine (Omnica Laboratories)

Development stage
Phase 3
Lead developer
Omnica Laboratories
Modality
Small Molecules
Administration
Oral
01

Overview

RINZ is an oral anticold combination tablet developed and manufactured by Omnica Laboratories in Nepal. It contains chlorpheniramine maleate (4 mg), phenylephrine hydrochloride (10 mg), and paracetamol (500 mg). Chlorpheniramine is a first-generation antihistamine that acts as an antagonist at the histamine H1 receptor to alleviate allergic symptoms such as sneezing and runny nose. Phenylephrine is a selective alpha-1 adrenergic receptor agonist that acts as a decongestant by causing vasoconstriction in the nasal mucosa. Paracetamol (acetaminophen) is an analgesic and antipyretic agent that inhibits prostaglandin synthesis, primarily via cyclooxygenase (COX) enzymes, to reduce pain and fever. RINZ is indicated for the symptomatic relief of common cold, allergic rhinitis, and associated fever and body aches.

Brand names
RINZ
Other names
chlorphenamine + paracetamol + phenylephrinechlorpheniramine + acetaminophen + phenylephrinechlorpheniramine maleate + paracetamol + phenylephrine hydrochloride
02

Targets

ADRA1A (α1A)ADRB1 (β1)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on chlorpheniramine + paracetamol + phenylephrine (Omnica Laboratories).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on chlorpheniramine + paracetamol + phenylephrine (Omnica Laboratories).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call